{
  "source": "PA-Notification-Simponi.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 1094-15\nProgram Prior Authorization/Notification\nMedication *Simponi® (golimumab)\n*This program applies to the subcutaneous formulation of golimumab.\nP&T Approval Date 1/2007, 6/2008 , 4/2009, 6/2009, 12/2009, 7/2010, 11/2010, 7/2011,\n11/2011, 7/2012, 8/2012, 11/2012, 7/2013, 2/2014, 2/2015, 4/2015,\n3/2016, 3/2017, 3/2018, 3/2019, 3/2020, 3/2021, 12/2021, 12/2022,\n7/2023, 10/2024\nEffective Date 1/1/2025\n1. Background:\nSimponi (golimumab) is a tumor necrosis factor (TNF) blocker, indicated for the treatment of\nadult patients with moderately to severely active rheumatoid arthritis (RA) in combination with\nmethotrexate (MTX).1 Simponi, alone or in combination with methotrexate, is indicated for the\ntreatment of adult patients with active psoriatic arthritis (PsA).1 It is also indicated for the\ntreatment of adult patients with active ankylosing spondylitis (AS).1 Simponi is also indicated\nin adult patients with moderate to severe ulcerative colitis who have require continuous steroid\ntherapy or who have had an inadequate response to or intolerance to prior treatment. For\nulcerative colitis, it is indicated for inducing and maintaining clinical response, improving\nendoscopic appearance of the mucosa during induction, inducing clinical remission, and\nachieving and sustaining clinical remission in induction responders.1 An intravenous\nformulation of golimumab, Simponi Aria®, is also available. Simponi Aria® is indicated for\nadult patients with moderately to severely active rheumatoid arthritis, active\npsoriatic arthritis, active ankylosing spondylitis, and active polyarticular juvenile idiopathic\narthritis.\n2. Coverage Criteriaa:\nA. Rheumatoid Arthritis (RA)\n1. Initial Authorization\na. Simponi will be approved based on both of the following criteria:\n(1) Diagnosis of moderately to severely active rheumatoid arthritis\n-AND-\n(2) Patient is not receiving Simponi in combination with another targeted\nimm",
    "pproved based on both of the following criteria:\n(1) Diagnosis of moderately to severely active rheumatoid arthritis\n-AND-\n(2) Patient is not receiving Simponi in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Orencia\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\n© 2024 UnitedHealthcare Services, Inc.\n1\na. Simponi will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Simponi therapy\n-AND-\n(2) Patient is not receiving Simponi in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Orencia\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib)]\nAuthorization will be issued for 12 months.\nB. Psoriatic Arthritis (PsA)\n1. Initial Authorization\na. Simponi will be approved based on both of the following criteria:\n(1) Diagnosis of active psoriatic arthritis\n-AND-\n(2) Patient is not receiving Simponi in combination with another immunomodulator\n[e.g., Enbrel (etanercept), Cimzia (certolizumab), Orencia (abatacept),\nadalimumab, Stelara (ustekinumab), Skyrizi (risankizumab), Tremfya\n(guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Simponi will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Simponi therapy\n-AND-\n(2) Patient is not receiving Simponi in combination with another immunomodulator\n[e.g., Enbrel (etanercept), Cimzia (certolizumab), Orencia (abatacept),\nadalimumab, Stelara (ustekinumab), Skyrizi (risankizumab), Tremfya\n(guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otez",
    "\nadalimumab, Stelara (ustekinumab), Skyrizi (risankizumab), Tremfya\n(guselkumab), Cosentyx (secukinumab), Taltz (ixekizumab), Xeljanz\n(tofacitinib), Olumiant (baricitinib), Rinvoq (upadacitinib), Otezla (apremilast)]\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services, Inc.\n2\nC. Ankylosing Spondylitis (AS)\n1. Initial Authorization\na. Simponi will be approved based on both of the following criteria:\n(1) Diagnosis of active ankylosing spondylitis\n-AND-\n(2) Patient is not receiving Simponi in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Orencia\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Simponi will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Simponi therapy\n-AND-\n(2) Patient is not receiving Simponi in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Orencia\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib)]\nAuthorization will be issued for 12 months.\nD. Ulcerative Colitis (UC)\n1. Initial Authorization\na. Simponi will be approved based on all of the following criteria:\n(1) Diagnosis of moderately to severely active ulcerative colitis\n-AND-\n(2) One of the following:\n(a) Patient is corticosteroid dependent (i.e., an inability to successfully taper\ncorticosteroids without a return of the symptoms of UC)\n(b) History of inadequate response or failure to tolerate one of the following:\ni. Oral aminosalicylates\nii. Oral corticosteroids\n© 2024 UnitedHealthcare Services, Inc.\n3\niii. Azathioprine\niv. 6-mercaptopurine\n-AND-\n(3) Patient is not receiving Simponi in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Orencia\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (bari",
    " is not receiving Simponi in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Orencia\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib)]\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Simponi will be approved based on both of the following criteria:\n(1) Documentation of positive clinical response to Simponi therapy\n-AND-\n(2) Patient is not receiving Simponi in combination with another targeted\nimmunomodulator [e.g., Enbrel (etanercept), Cimzia (certolizumab), Orencia\n(abatacept), adalimumab, Xeljanz (tofacitinib), Olumiant (baricitinib), Rinvoq\n(upadacitinib)]\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by\nprogram and/or therapeutic class.\n• Supply limits and/or Step Therapy may be in place.\n• The intravenous infusion is typically covered under the medical benefit. Please refer to the\nUnited Healthcare Drug Policy for Simponi Aria\n4. References:\n1. Simponi [package insert]. Horsham, PA: Janssen Biotech Inc.; September 2019.\n2. Simponi Aria [package insert]. Horsham, PA: Janssen Biotech, Inc.; February 2021.\n© 2024 UnitedHealthcare Services, Inc.\n4\nProgram Prior Authorization/Notification – Simponi (golimumab)\nChange Control\n2/2014 Extended reauthorization duration to 24 months.\n9/2014 Administrative change – Tried/Failed exemption for State of New\nJersey removed.\n2/2015 Annual review with no change to coverage criteria. Minor reformatting.\nUpdated background and references.\n",
    "9/2014 Administrative change – Tried/Failed exemption for State of New\nJersey removed.\n2/2015 Annual review with no change to coverage criteria. Minor reformatting.\nUpdated background and references.\n4/2015 Changed initial UC authorization from 10 weeks to 12 weeks.\n3/2016 Annual review. Updated background information. Added Otezla\n(apremilast) to the combination criteria for psoriatic arthritis. Updated\nstatement regarding scope of the program. Added reference to the UHC\ndrug policy for intravenous infusions. Updated references.\n3/2017 Annual review with no changes to coverage criteria. Updated\nbackground and references.\n3/2018 Annual review with no changes to coverage criteria. Updated\nreferences.\n3/2019 Annual review. Added Olumiant (baricitinib) to list of medications that\npatient should not be receiving while on Simponi therapy for\nrheumatoid arthritis. Updated references.\n3/2020 Annual review. Added Rinvoq (upadacitinib) to list of medications that\npatient should not be receiving while on Simponi therapy for\nrheumatoid arthritis. Updated references.\n3/2021 Annual review. No changes to clinical criteria. Updated background.\n12/2021 Updated initial authorization for UC to 12 months.\n12/2022 Annual review with no change to coverage criteria. Added Rinvoq as a\nJAK inhibitor example. Updated reference and background. Added\nstate mandate footnote.\n7/2023 Updated not receiving in combination language to targeted\nimmunomodulator and updated examples.\n10/2024 Annual review with no change to coverage criteria.\n© 2024 UnitedHealthcare Services, Inc.\n5"
  ]
}